Medigene's Veregen® launched in Spain
(Thomson Reuters ONE) -
MediGene AG /
Medigene's Veregen® launched in Spain
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, June 5th, 2012. Medigene AG (MDG, Frankfurt, Prime Standard)
(MDG, Frankfurt, Prime Standard) announced today that its partner BIAL
Industrial Farmacéutica, S.A. has started the launch of Veregen(®), for the
treatment of genital warts, in Spain. Following Germany and Austria, Spain is
the third European market where Veregen(®) is available. In addition, Veregen(®)
is also being marketed in the United States. Medigene supplies BIAL with the
drug product, and will receive royalties on sales achieved with Veregen(®).
Dr. Frank Mathias, Chief Executive Officer of Medigene AG, commented: "The
market launch in Spain, one of the five major European markets, represents a
significant step forward in the commercialization of Veregen(®). Through the
marketing activities of our partner BIAL, we are pleased to offer this
innovative drug to patients in Spain."
Market approvals for Veregen(®) have been obtained in Switzerland, Poland,
Sweden, Norway, and Serbia. In March 2012, marketing authorization applications
for numerous additional European countries were assessed positively by the
regulatory authorities. Medigene expects that the national marketing
authorizations will be formally granted by the respective regulatory authorities
within the next few months.
Medigene has entered into several marketing partnerships for Veregen(®),
including Fougera for the United States; Abbott for Germany, Austria, and
Switzerland; Laboratoires Expanscience for France; and a number of other
partners across Europe, America, and Asia. Medigene is planning to continue this
global licensing strategy.
Veregen(®): Veregen(®) (previously Polyphenon E(®) ointment), a topical
treatment for external genital warts, contains a concentrate of catechins with a
complex defined composition extracted from green tea leaves. Medigene acquired
the basic rights to the active ingredient in Veregen(®) from Epitome
Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's
successful preclinical and clinical development, as well as the approval
process. Sinecatechins 15% ointment (Veregen(®)) is recommended as a possible
option for treating genital warts by the US Department of Health and Human
Services Center for Disease Control and Prevention's Sexually Transmitted
Diseases Treatment Guidelines 2010.
About BIAL: BIAL, founded in 1924, is a global pharmaceutical company with
products marketed in 50 countries on 4 continents. The privately owned company
ranks number 5 on the Portuguese pharmaceutical market and has a strong presence
on the Iberian Peninsula, in Latin America as well as in French and Portuguese
speaking countries in Africa. BIAL is strongly committed to therapeutic
innovation investing more than 25% of its turnover in research and development
every year. BIAL currently has several innovative programs under development,
which the company expects to bring to the market within the next years, thereby
strengthening its position throughout Europe. For further details, please visit
www.bial.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
- End -
Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials and is developing an innovative vaccine
technology. For more information, please visit www.medigene.com.
Contact
Julia Hofmann & Kerstin Langlotz
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as pdf:
http://hugin.info/132073/R/1617176/515951.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1617176]
Unternehmensinformation / Kurzprofil:
Datum: 05.06.2012 - 07:31 Uhr
Sprache: Deutsch
News-ID 152937
Anzahl Zeichen: 5888
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 253 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene's Veregen® launched in Spain"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
